Overview

The Division of Hematologic Malignancies & Cellular Therapy is a flagship Division in the Duke Department of Medicine. The Division is integrated as a Program within the Duke Cancer Institute, one of the original eight National Cancer Institute designated Comprehensive Cancer Centers, and a single entity that draws from researchers and physicians across various departments and schools at Duke to advance cancer care and research. We have a diverse faculty with excellence in clinical care, teaching, and research.

Our faculty are among national and international leaders in leukemia, lymphoma, myeloma, hematopoietic cell transplantation, and graft-vs-host disease (GvHD). We also have faculty that are leaders in cellular therapies such as CAR-T, myeloproliferative neoplasms, amyloidosis, and transplantation for non-cancer diseases such as scleroderma and autoimmune diseases.

Our Mission

The mission of the Duke Division of Hematologic Malignancies & Cellular Therapy is to promote health and improve lives by preventing, diagnosing, and treating blood cancer and other life threatening diseases through integrated, innovative, and holistic patient care, education, and research.

The Hematologic Malignancies & Cellular Therapy (HMCT) Program is a multidisciplinary basic, translational, and clinical research program whose overall goal is to improve outcomes for patients with hematologic malignancies. The broad, long-term goal of the HMCT Program is to build on and extend the current knowledge in the fields of leukemia, lymphoma, myeloma, hematopoietic cell transplantation, and immunotherapy, and to develop and implement novel strategies for improving therapeutic results in these patients through a collaborative and integrated approach involving all the investigators in the program.

Regular Rank Faculty Facts & Figures

- 32 Faculty (including 2 secondary appointments)
- 9 faculty with tenure
- 20/12 Male/Female

Breakdown by Rank:

- 3 Medical Instructors
- 9 Assistant Professors
- 7 Associate Professors
- 13 Professors
Specific Highlights or Roles/Responsibilities

Clinical Responsibilities:

The Division provides clinical services that span the entire spectrum of hematologic oncology and hematopoietic cell transplantation for 100+ diagnoses.

- Working with Duke leadership, provide input and collaborate on Oncology services of DUHS for strategic planning, innovative care models, quality improvement and academic activities.

- Understand clinical operations carried out by Duke University Health System and the Private Diagnostic Clinic as it relates to hematologic oncology and cellular therapy.

- Shepherd the HMCT Division into the new vertically integrated Duke Health Integrated Practice (DHIP) model.

Important to Note:

- The Division provides comprehensive ambulatory care for patients at hospital-based clinics at both Duke University Hospital (DUH) and Duke Raleigh Hospital (DRAH).

- Our clinical services that span the entire spectrum of hematologic oncology and hematopoietic cell transplantation for 100+ diagnoses.

- Additionally, the Division provides rounding coverage for three service lines at DUH:
  - Outpatient BMT Service – held at the ABMT Clinic’s “day hospital”, the service is staffed by 1 BMT attending that provides treatment coverage 365 days/per for patients undergoing active transplant outpatient. Service is supplemented with APP’s.
  - Inpatient BMT Service – 10A Inpatient Unit; staffed by 1 BMT attending and supplemented with APP’s.
  - Inpatient Hem/Onc Service – 10B/9200 Inpatient Unit; this service is exclusive for hematologic malignancies and is staffed by 3 hematologic malignancy attendings and supplemented with APP’s, residents, and a fellow.

A Snapshot of Clinical Mission:

- 15.8 M.D. cFTE
- 44 APP cFTE (18.5 FTEs funded by DUHS)
- $ 26.7M in Charges
- $ 8.7M in Receipts
- 1,727 New OP Visit
- 115,795 wRVUs
- 28,383 Total OP Visits
- 22,643 Inpatient E&Ms
- 222 Annual Transplants (6,800 since inception)
- 30 Annual Commercial CAR-Ts (99 since inception)
Research Responsibilities:
The Division maintains a multidisciplinary research portfolio with contributions from clinical and laboratory-based investigation

- Promote research activities within the Division and the Cancer Institute to meet goals for scholarly activity, including number of grant submissions, marshalling resources for research, encouraging collaborative interactions
- Oversee a vibrant basic, translational and clinical research program within the Division/Department of Medicine and the Duke Cancer Institute
- Direct mentoring or identification of mentors for junior faculty and fellow research development

Important to Note:
The Division maintains a multidisciplinary research portfolio with contributions from clinical and laboratory-based investigation. Specific aims of the research program include:

- To understand hematopoietic stem cell biology and optimize stem cell graft for allogeneic and autologous stem cell transplantation
- To understand the basic biology of graft vs tumor (GvT) and graft vs host disease (GvHD), and to improve GvT without significant GvHD
- To understand the biology of T, B, and NK cells and develop novel immunotherapeutic strategies
- To develop genomic structures for hematologic malignancies and understand mechanisms underlying leukemogenesis or lymphomagenesis
- To design and execute novel Phase 1 and Phase II clinical trials in hematologic malignancies based on novel laboratory discoveries within the program.
- As a complement to these efforts, we partner with the Duke Cancer Institute to offer over 100 active clinical trials specific to hematologic malignancies and transplantation, ranging from Phase I “first in human” studies to Phase III randomized studies.

A Snapshot of Research Mission:

- 24 PIs with active awards ($2.75M average in active awards per PI)
- $66M in active awards (158 projects)
- 33 pending proposals
- 26% of active awards funding is federal
- 85% of active awards funding has human subjects
- 8 ‘R’ federal awards
- 2 ‘U’ federal awards
- 0 ‘K’ federal awards
- $1.27M in Division-owned indirects
**Educational Responsibilities:**

- Train future leaders in the fields of hematologic oncology and hematopoietic cell transplantation through a variety of teaching opportunities.

- Share in the oversight of the Fellowship program as well as faculty education and training programs in hematological oncology and cellular therapy. Key education highlights noted below

**Important to Note:**

The Division is committed to training future leaders in the fields of hematologic oncology and hematopoietic cell transplantation through a variety of teaching opportunities.

- **Hematology-Oncology Fellowship Program**  
  Co-managed by the three Medicine Divisions of Hematologic Malignancies & Cellular Therapy, Medical Oncology, and Hematology, the Fellowship Program provides modern clinical training in the comprehensive care of cancer patients and in the diagnosis and management of hematologic disease as well as bench-to-bedside research and laboratory training. With the broad diversity amongst the three Divisions, the program offers a variety of options for interested fellows in subspecialty areas.

- **Internal Medicine Residency Program**  
  Managed centrally in the Department of Medicine, our Division faculty teach and collaborate with our residents on the Inpatient 9100 Hem/Onc Service.

**Administrative Responsibilities:**

- Help shape and strengthen the oncology programs in the Division of Hematologic Malignancies and Cellular Therapy and the Duke Cancer Institute

- Lead Divisional strategic planning and participate in Departmental strategic planning processes

- Ensure Divisional fiscal soundness

- Oversee the growth and development of the faculty, trainees and staff

**Requirements**

- MD degree, Board Certified in Hematology and/or Oncology

- Commitment to academic excellence

---

Other Key Facts:

- **68** Total Number of Employed (Non-Faculty) Staff
- **$15M** Clinical Budget
- **$2.5M** Academic (University) Budget
- **$17.5M** Total Operating Budget